Tasly Pharmaceutical Group Statistics

Total Valuation

Tasly Pharmaceutical Group has a market cap or net worth of CNY 21.36 billion. The enterprise value is 18.54 billion.

Market Cap	21.36B
Enterprise Value	18.54B

Important Dates

The next estimated earnings date is Monday, October 28, 2024.

Earnings Date	Oct 28, 2024
Ex-Dividend Date	May 29, 2024

Share Statistics

Tasly Pharmaceutical Group has 1.49 billion shares outstanding. The number of shares has increased by 1.47% in one year.

Shares Outstanding	1.49B
Shares Change (YoY)	+1.47%
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	0.06%
Owned by Institutions (%)	10.09%
Float	765.53M

Valuation Ratios

The trailing PE ratio is 20.78 and the forward PE ratio is 14.74. Tasly Pharmaceutical Group's PEG ratio is 0.53.

PE Ratio	20.78
Forward PE	14.74
PS Ratio	2.46
PB Ratio	1.70
P/FCF Ratio	10.42
PEG Ratio	0.53

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.54, with an EV/FCF ratio of 9.04.

EV / Earnings	18.06
EV / Sales	2.14
EV / EBITDA	9.54
EV / EBIT	12.70
EV / FCF	9.04

Financial Position

The company has a current ratio of 2.95, with a Debt / Equity ratio of 20.68.

Current Ratio	2.95
Quick Ratio	2.37
Debt / Equity	20.68
Debt / EBITDA	1.37
Debt / FCF	1.30
Interest Coverage	17.34

Financial Efficiency

Return on equity (ROE) is 7.75% and return on invested capital (ROIC) is 5.83%.

Return on Equity (ROE)	7.75%
Return on Assets (ROA)	5.24%
Return on Capital (ROIC)	5.83%
Revenue Per Employee	938,280
Profits Per Employee	111,275
Employee Count	9,223
Asset Turnover	0.50
Inventory Turnover	1.62

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +3.40% in the last 52 weeks. The beta is 0.37, so Tasly Pharmaceutical Group's price volatility has been lower than the market average.

Beta (5Y)	0.37
52-Week Price Change	+3.40%
50-Day Moving Average	13.55
200-Day Moving Average	15.05
Relative Strength Index (RSI)	57.16
Average Volume (20 Days)	13,627,051

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Tasly Pharmaceutical Group had revenue of CNY 8.65 billion and earned 1.03 billion in profits. Earnings per share was 0.69.

Revenue	8.65B
Gross Profit	5.83B
Operating Income	1.46B
Pretax Income	1.18B
Net Income	1.03B
EBITDA	1.86B
EBIT	1.46B
Earnings Per Share (EPS)	0.69

Full Income Statement

Balance Sheet

The company has 5.80 billion in cash and 2.66 billion in debt, giving a net cash position of 3.14 billion or 2.10 per share.

Cash & Cash Equivalents	5.80B
Total Debt	2.66B
Net Cash	3.14B
Net Cash Per Share	2.10
Equity (Book Value)	12.84B
Book Value Per Share	8.39
Working Capital	6.45B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.62 billion and capital expenditures -571.77 million, giving a free cash flow of 2.05 billion.

Operating Cash Flow	2.62B
Capital Expenditures	-571.77M
Free Cash Flow	2.05B
FCF Per Share	1.37

Full Cash Flow Statement

Margins

Gross margin is 67.38%, with operating and profit margins of 16.87% and 11.86%.

Gross Margin	67.38%
Operating Margin	16.87%
Pretax Margin	13.69%
Profit Margin	11.86%
EBITDA Margin	21.52%
EBIT Margin	16.87%
FCF Margin	23.68%

Dividends & Yields

This stock pays an annual dividend of 0.52, which amounts to a dividend yield of 3.64%.

Dividend Per Share	0.52
Dividend Yield	3.64%
Dividend Growth (YoY)	-50.00%
Years of Dividend Growth	n/a
Payout Ratio	53.79%
Buyback Yield	-1.47%
Shareholder Yield	2.16%
Earnings Yield	4.81%
FCF Yield	9.59%

Dividend Details

Stock Splits

The last stock split was on June 5, 2018. It was a forward split with a ratio of 1.4.

Last Split Date	Jun 5, 2018
Split Type	Forward
Split Ratio	1.4